Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Researchers repair gene mutation responsible for muscular dystrophy in dogs

June 23, 2000

Exelon now available in U.S. for treatment of Alzheimer's

June 22, 2000

Monoamine reuptake inhibitors designed by Faes particularly useful as antidepressants

June 21, 2000

Licensing opportunity from NIH: conjugated cell toxins for chronic pain

June 21, 2000

University researchers shed new light on neurodegenerative diseases

June 21, 2000

Coffee and caffeine intake and risk of Parkinson's disease

June 21, 2000

Lanepitant proves ineffective in reducing osteoarthritis pain

June 20, 2000

Celgene and Novartis d-methylphenidate license agreement now in effect

June 20, 2000

Licensing opportunity from NIH: neuropeptide for pain regulation, blood pressure control

June 20, 2000

Neurocrine Biosciences patents new CRF antagonists

June 19, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...